Undisclosed trispecific antibody / Antengene - LARVOL DELTA

Additional TCE programs for solid tumors (PRNewswire) - "Antengene plans to submit an IND for ATG-110 (LY6G6D × CD3 TCE) in the first half of 2027 for the treatment of microsatellite-stable colorectal cancer. In addition, ATG-115 (an undisclosed bispecific antibody) and two undisclosed trispecific antibody programs are currently in preclinical development."

IND • Preclinical • Colorectal Cancer